JP2023109992A5 - - Google Patents

Info

Publication number
JP2023109992A5
JP2023109992A5 JP2023089121A JP2023089121A JP2023109992A5 JP 2023109992 A5 JP2023109992 A5 JP 2023109992A5 JP 2023089121 A JP2023089121 A JP 2023089121A JP 2023089121 A JP2023089121 A JP 2023089121A JP 2023109992 A5 JP2023109992 A5 JP 2023109992A5
Authority
JP
Japan
Prior art keywords
item
nucleotide sequence
composition
nucleic acid
acid molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023089121A
Other languages
English (en)
Japanese (ja)
Other versions
JP7888501B2 (ja
JP2023109992A (ja
Filing date
Publication date
Priority claimed from PCT/EP2018/063707 external-priority patent/WO2018215613A1/en
Application filed filed Critical
Publication of JP2023109992A publication Critical patent/JP2023109992A/ja
Publication of JP2023109992A5 publication Critical patent/JP2023109992A5/ja
Priority to JP2026059364A priority Critical patent/JP2026119083A/ja
Application granted granted Critical
Publication of JP7888501B2 publication Critical patent/JP7888501B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023089121A 2017-05-24 2023-05-30 線維芽細胞増殖因子21(fgf21)コーディング配列を含むウイルス発現コンストラクト Active JP7888501B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026059364A JP2026119083A (ja) 2017-05-24 2026-03-31 線維芽細胞増殖因子21(fgf21)コーディング配列を含むウイルス発現コンストラクト

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
ES201700615 2017-05-24
EP17172818 2017-05-24
EP17172818.1 2017-05-24
ES201700615 2017-05-24
PCT/EP2018/063707 WO2018215613A1 (en) 2017-05-24 2018-05-24 Viral expression construct comprising a fibroblast growth factor 21 (fgf21) coding sequence
JP2019565341A JP7778469B2 (ja) 2017-05-24 2018-05-24 線維芽細胞増殖因子21(fgf21)コーディング配列を含むウイルス発現コンストラクト

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2019565341A Division JP7778469B2 (ja) 2017-05-24 2018-05-24 線維芽細胞増殖因子21(fgf21)コーディング配列を含むウイルス発現コンストラクト

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026059364A Division JP2026119083A (ja) 2017-05-24 2026-03-31 線維芽細胞増殖因子21(fgf21)コーディング配列を含むウイルス発現コンストラクト

Publications (3)

Publication Number Publication Date
JP2023109992A JP2023109992A (ja) 2023-08-08
JP2023109992A5 true JP2023109992A5 (cg-RX-API-DMAC7.html) 2025-08-26
JP7888501B2 JP7888501B2 (ja) 2026-07-13

Family

ID=62620819

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019565341A Active JP7778469B2 (ja) 2017-05-24 2018-05-24 線維芽細胞増殖因子21(fgf21)コーディング配列を含むウイルス発現コンストラクト
JP2023089121A Active JP7888501B2 (ja) 2017-05-24 2023-05-30 線維芽細胞増殖因子21(fgf21)コーディング配列を含むウイルス発現コンストラクト
JP2026059364A Pending JP2026119083A (ja) 2017-05-24 2026-03-31 線維芽細胞増殖因子21(fgf21)コーディング配列を含むウイルス発現コンストラクト

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2019565341A Active JP7778469B2 (ja) 2017-05-24 2018-05-24 線維芽細胞増殖因子21(fgf21)コーディング配列を含むウイルス発現コンストラクト

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026059364A Pending JP2026119083A (ja) 2017-05-24 2026-03-31 線維芽細胞増殖因子21(fgf21)コーディング配列を含むウイルス発現コンストラクト

Country Status (8)

Country Link
US (1) US20200102361A1 (cg-RX-API-DMAC7.html)
EP (1) EP3630160A1 (cg-RX-API-DMAC7.html)
JP (3) JP7778469B2 (cg-RX-API-DMAC7.html)
CN (1) CN110913886A (cg-RX-API-DMAC7.html)
AU (2) AU2018274655B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019024608A2 (cg-RX-API-DMAC7.html)
MX (1) MX2019013982A (cg-RX-API-DMAC7.html)
WO (1) WO2018215613A1 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102765034B1 (ko) 2017-05-24 2025-02-11 유니버시타트 아우토노마 데 바르셀로나 섬유아세포 성장 인자 21 (fgf21) 코딩 서열을 포함하는 바이러스 발현 컨스트럭트
BR112019024608A2 (pt) * 2017-05-24 2020-06-23 Universitat Autonoma De Barcelona Construto de expressão viral que compreende uma sequência de codificação do fator de crescimento de fibroblastos 21 (fgf21)
GB201818816D0 (en) * 2018-11-19 2019-01-02 Synpromics Ltd Regulatory nucleic acid sequences
IL283452B2 (en) * 2018-11-26 2026-04-01 Univ Barcelona Autonoma FIBROBLAST GROWTH FACTOR 21 (FGF21)-BASED GENE THERAPY
ES2948620T3 (es) 2019-07-10 2023-09-14 Masonic Medical Res Laboratory Vgll4 con elemento regulador CIS de UCP-1 y método de uso del mismo
MX2022004353A (es) 2019-10-17 2022-07-19 Casete de transferencia de aav.
CN115916985A (zh) * 2020-05-26 2023-04-04 巴塞罗那自治大学 用于中枢神经系统障碍的成纤维细胞生长因子21(fgf21)基因疗法
CN113956344A (zh) * 2021-10-14 2022-01-21 江南大学 一种新型治疗肝癌的fgf类似物及其应用
CN114010666B (zh) * 2021-10-22 2024-05-07 上海交通大学 溶瘤病毒、parp抑制剂及pd-1抗体在制备抗肿瘤药物中的应用
CN114316018A (zh) * 2021-11-26 2022-04-12 江南大学 一种fgf21蛋白类似物及其应用
CN118460618A (zh) * 2022-04-19 2024-08-09 康霖生物科技(杭州)有限公司 一种用于遗传性凝血因子缺乏病治疗的核酸构建体
EP4598590A4 (en) * 2022-10-08 2026-05-27 Lingyi Biotech Co Ltd CONSTRUCTION TO IMPROVE GENE EXPRESSION
WO2025158406A1 (en) * 2024-01-26 2025-07-31 Source Bio, Inc. Compositions for adipose tissue targeting and uses thereof
CN118389554A (zh) * 2024-05-10 2024-07-26 三峡大学 一种提高fgf-21持续表达水平和稳定性的aav重组病毒及其应用
WO2025240610A2 (en) * 2024-05-14 2025-11-20 Rejuvenate Bio Inc Fgf21 gene therapy and methods therefor
WO2026028137A1 (en) * 2024-07-31 2026-02-05 Universitat Autònoma De Barcelona Fibroblast growth factor 21 (fgf21) gene therapy
WO2026133103A1 (en) * 2024-12-16 2026-06-25 Universitat Autònoma De Barcelona Aav vectors for delivery of nucleic acids encoding fgf21 and methods of treating lung diseases using the same

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
US6268213B1 (en) 1992-06-03 2001-07-31 Richard Jude Samulski Adeno-associated virus vector and cis-acting regulatory and promoter elements capable of expressing at least one gene and method of using same for gene therapy
US5869305A (en) 1992-12-04 1999-02-09 The University Of Pittsburgh Recombinant viral vector system
US5464758A (en) 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
US6204059B1 (en) 1994-06-30 2001-03-20 University Of Pittsburgh AAV capsid vehicles for molecular transfer
US5741683A (en) 1995-06-07 1998-04-21 The Research Foundation Of State University Of New York In vitro packaging of adeno-associated virus DNA
US6093570A (en) 1995-06-07 2000-07-25 The University Of North Carolina At Chapel Hill Helper virus-free AAV production
US5952221A (en) 1996-03-06 1999-09-14 Avigen, Inc. Adeno-associated virus vectors comprising a first and second nucleic acid sequence
US6133027A (en) 1996-08-07 2000-10-17 City Of Hope Inducible expression system
EP1007637B1 (en) 1997-04-14 2004-06-30 Cell Genesys, Inc. Methods for increasing the efficiency of recombinant aav product
US6207455B1 (en) 1997-05-01 2001-03-27 Lung-Ji Chang Lentiviral vectors
CN1247788C (zh) 1997-05-13 2006-03-29 北卡罗来纳-查佩尔山大学 基于慢病毒的基因转移载体
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US6218181B1 (en) 1998-03-18 2001-04-17 The Salk Institute For Biological Studies Retroviral packaging cell line
US6146874A (en) 1998-05-27 2000-11-14 University Of Florida Method of preparing recombinant adeno-associated virus compositions
EP1135468B1 (en) 1998-11-10 2010-01-06 University Of North Carolina At Chapel Hill Virus vectors and methods of making and administering the same
DE19909769A1 (de) 1999-03-05 2000-09-07 Bundesrepublik Deutschland Let Von SIVagm abgeleitete lentivirale Vektoren, Verfahren zu ihrer Herstellung und ihre Verwendung zur Genübertragung in Säugerzellen
AU6814901A (en) 2000-06-01 2001-12-11 Univ North Carolina Methods and compounds for controlled release of recombinant parvovirus vectors
AU2001292881A1 (en) * 2000-09-20 2002-04-02 The Regents Of The University Of California Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
AU2003274397A1 (en) 2002-06-05 2003-12-22 University Of Florida Production of pseudotyped recombinant aav virions
US8951966B2 (en) * 2011-07-01 2015-02-10 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides, and uses and methods thereof for treatment of metabolic disorders and diseases
WO2013033452A2 (en) * 2011-08-31 2013-03-07 Amgen Inc. Method of treating or ameliorating type 1 diabetes using fgf21
EP2692868A1 (en) * 2012-08-02 2014-02-05 Universitat Autònoma De Barcelona Adeno-associated viral (AAV) vectors useful for transducing adipose tissue
US9290557B2 (en) * 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
EP3798228A1 (en) * 2012-11-28 2021-03-31 NGM Biopharmaceuticals, Inc. Compositions and methods for treatment of metabolic disorders and diseases
CN105916990B (zh) * 2013-08-02 2020-02-04 巴塞罗那自治大学 用于转导脂肪组织的腺相关病毒载体
CN109844124B (zh) * 2016-05-20 2023-10-03 哈佛学院董事及会员团体 年龄相关疾病和病症的基因治疗方法
BR112019024608A2 (pt) 2017-05-24 2020-06-23 Universitat Autonoma De Barcelona Construto de expressão viral que compreende uma sequência de codificação do fator de crescimento de fibroblastos 21 (fgf21)
IL283452B2 (en) * 2018-11-26 2026-04-01 Univ Barcelona Autonoma FIBROBLAST GROWTH FACTOR 21 (FGF21)-BASED GENE THERAPY

Similar Documents

Publication Publication Date Title
JP2023534999A5 (cg-RX-API-DMAC7.html)
JP2022500066A5 (cg-RX-API-DMAC7.html)
JP2023544683A5 (cg-RX-API-DMAC7.html)
RU2018129159A (ru) Рекомбинантные aav векторы, экспрессирующие остеопротективные гены, включая has2 и лубрицин, пригодные при лечении остеоартрита и сходных заболеваний суставов у млекопитающих
JP2020203894A5 (cg-RX-API-DMAC7.html)
JP2021531752A5 (cg-RX-API-DMAC7.html)
JP2023534037A5 (cg-RX-API-DMAC7.html)
JP2022531809A5 (cg-RX-API-DMAC7.html)
JP2021512649A5 (cg-RX-API-DMAC7.html)
US10494619B2 (en) High isomerohydrolase activity mutants of human RPE65
JP2023535956A5 (cg-RX-API-DMAC7.html)
JP2023088902A5 (cg-RX-API-DMAC7.html)
JP2024523707A5 (cg-RX-API-DMAC7.html)
JP2023515072A5 (cg-RX-API-DMAC7.html)
JP2025120285A5 (cg-RX-API-DMAC7.html)
JP2021500922A5 (cg-RX-API-DMAC7.html)
US20200102361A1 (en) Viral expression construct comprising a fibroblast growth factor 21 (fgf21) coding sequence
JP2024518817A5 (cg-RX-API-DMAC7.html)
JP2024530023A5 (cg-RX-API-DMAC7.html)
JP2021525531A5 (cg-RX-API-DMAC7.html)
JP2024518665A5 (cg-RX-API-DMAC7.html)
JP2024545186A5 (cg-RX-API-DMAC7.html)
JP2023544702A5 (cg-RX-API-DMAC7.html)
JP2021529519A5 (cg-RX-API-DMAC7.html)
KR101756131B1 (ko) 간세포 성장인자 및 기질세포 유발인자1알파를 이용한 말초동맥질환의 예방 또는 치료용 조성물